VIP 10mg
VIP (VASOACTIVE INTESTINAL PEPTIDE)
VIP is a 28-amino acid neuropeptide with potent anti-inflammatory, immunomodulatory, and neuroprotective effects. It works through VPAC1 and VPAC2 receptors to suppress pro-inflammatory cytokines (IL-6, TNF-α, TGF-β1) and regulate immune cell differentiation.
VIP has been extensively studied for chronic inflammatory response syndrome (CIRS), autoimmune conditions, pulmonary inflammation, and COVID-19 respiratory failure. The injectable form (Aviptadil/Zyesami) received FDA Fast Track designation.
Mechanism of Action
VIP binds VPAC receptors coupled to Gas proteins, activating adenylate cyclase and increasing cAMP/PKA signaling. This cascade inhibits pro-inflammatory cytokines, modulates T helper cell differentiation, regulates innate and adaptive immunity, and provides neuroprotection.
Potential Benefits
Potent anti-inflammatory and immunomodulatory effects
Neuroprotection and circadian rhythm regulation
Correction of CIRS inflammatory markers (TGF-β1, lipase)
Pulmonary vasodilation and respiratory support
Cognitive and mood support
Reduced systemic inflammation in autoimmune conditions
Established clinical trial data (COVID-19 ARDS showed 2-fold increased 60-day survival)
Why It's Being Researched
VIP addresses systemic inflammation and immune dysregulation through a well-characterized receptor pathway. CIRS — a multi-system inflammatory condition triggered by water-damaged building exposure — shows dramatic response to VIP nasal spray, with correction of proteomics and gray matter atrophy refractory to other therapies. Recent Phase 2b/3 trials of IV Aviptadil in critical COVID-19 respiratory failure showed 2-fold increased survival odds, driving continued clinical interest.
Interesting Facts
VIP is one of the few peptides with FDA Fast Track status for a serious condition (COVID-19 ARDS)
VIP is extremely unstable — reconstituted injectable solutions degrade within 14–21 days even when refrigerated
First-dose labs (TGF-β1, lipase) are recommended to establish baseline and assess immediate response
Common early side effects include flushing, headaches, nausea, and loose stools — typically mild and transient
VIP synergizes with KPV and Thymosin Alpha-1 for multi-pathway immune regulation
Stacking With VIP
Synergistic
Thymosin Alpha-1 — both immunomodulatory peptides; complement each other in immune regulation
KPV — anti-inflammatory through different pathways (VIP via VPAC receptors, KPV via melanocortin system); work together for multi-pathway immune suppression
Compatible
BPC-157 — VIP modulates immune response; BPC-157 promotes tissue healing. Complementary for CIRS and inflammatory recovery
GHK-CU — VIP for systemic immune regulation; GHK-CU for tissue remodeling and copper delivery
LL-37 — VIP is anti-inflammatory; LL-37 is antimicrobial. May work together in CIRS protocols
Selank — both have anxiolytic and immunomodulatory effects through different receptor systems
DSIP — both involved in circadian regulation (VIP in suprachiasmatic nucleus, DSIP in sleep induction)
Cerebrolysin — contains VIP-like peptide fragments; both neuroprotective with overlapping mechanisms
Avoid
Immunosuppressants (corticosteroids, methotrexate) — may blunt VIP's immune-modulating effects; discuss timing with provider
Excessive stimulants (high-dose caffeine, amphetamines) — may counteract VIP's calming and circadian effects
RESEARCH PURPOSES ONLY
NOT AVAILABLE FOR HUMAN CONSUMPTION
